Agenus Inc.

Memorial Sloan Kettering Cancer Center

Ludwig Institute for Cancer Research Limited

Regenesance B.v.

Mink Therapeutics, Inc.

Marc A Van Dijk

Nicholas Stuart Wilson

Gerd J Ritter

Taha Merghoub

David Schaer

David Adam Savitsky

Cornelia Anne Mundt

Dennis John Underwood

Jedd David Wolchok

Ekaterina Vladimirovna Breous-Nystrom

Volker Seibert

Jeremy Dale Waight

Takemasa Tsuji

Olivier Léger

Daniel Hirschhorn-Cymerman

Mark Arthur Findeis

Roberta Zappasodi

Jean-Marie Cuillerot

Igor Proscurshim

Olga Shebanova

Hao Tang

Shawn Michael Jennings

Mark A Exley

Frank Baas

Ana M Gonzalez

Benjamin Jacob Wolf

Arthur Andrew Hurwitz

Sébastien Lalevée

Olga Ignatovich

Yanping Xiao

Benjamin Maxime Morin

Dhan Sidhartha Chand

Alessandra Franchino

Rikke Bæk Holmgaard

Rikke Baek Holmgaard

Reed Masakayan

Daniel Leventhal

Mark Adrian Exley

Provided are TCRs (e.g., TCRs that bind to MLL, e.g., TCRs that bind to an MLL phosphopeptide, e.g., TCRs that bind to an MLL phosphopeptide/MHC complex), cells and pharmaceutical compositions comprising these TCRs, nucleic acids encoding these TCRs, expression vectors and host cells for making these TCRs, and methods of treating a subject using these TCRs.

T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof

The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Anti-CTLA-4 antibodies and methods of use thereof

Isolated monoclonal antibodies that bind to human complement component C6 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic methods for using the antibodies.

Antibodies that bind human C6 and uses thereof

The instant disclosure provides antibodies that specifically bind to LAG-3 (e.g., human LAG-3) and antagonize LAG-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Anti-LAG-3 antibodies and methods of use thereof

The instant disclosure provides antibodies that specifically bind to TIM 3 and antagonize TIM-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Anti-TIM-3 antibodies and methods of use thereof

Anti-lag-3 antibodies and methods of use thereof

Provided are antibodies that specifically bind to CTLA-4 and/or PD-1 and antagonize CTLA-4 and/or PD-1 function. Also provided are pharmaceutical compositions and kits comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies either alone or in combination.

Antibodies and methods of use thereof

The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.

Anti-GITR antibodies and methods of use thereof

Antibodies that specifically bind to TIM 3 and antagonize TIM-3 function pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Provided are TCRs (e.g., TCRs that bind to NY-ESO-1), cells and pharmaceutical compositions comprising these TCRs, nucleic acids encoding these TCRs, expression vectors and host cells for making these TCRs, and methods of treating a subject using these TCRs.

T cell receptors that bind to NY-ESO-1 and methods of use thereof

The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.

Methods of administering anti-OX40 antibodies

The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.

Growing community of inventors

Amsterdam, Netherlands

Marc A Van Dijk